POTTERS BAR and PITTSBURGH, December 2014 -- Mylan Inc. (NASDAQ: MYL) today announced the UK launch of Lamotrigine dispersible tablets, 25 mg and 100 mg, which is the generic version of The Wellcome Foundation Ltd’s Lamictal® Dispersible. Mylan received final approval from the MHRA for this product, which is indicated for the treatment of Epilepsy and Bipolar Disorder.
Lamotrigine Tablets, 25 mg and 100 mg had UK sales of approximately 264,530 packs for the 12 months ending October 2014, according to IMS MAT.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.co.uk and mylan.com.